|Bid||4.7700 x 900|
|Ask||4.7900 x 1400|
|Day's Range||4.7101 - 4.8500|
|52 Week Range||2.9300 - 8.3300|
|Beta (5Y Monthly)||2.05|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 11, 2021 - Aug 16, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||16.00|
Preclinical candidate is second to demonstrate selective blocking ability from in-house panel of antibodies targeting NRP2. aNRP2-14 blocks Semaphorin 3F/NRP2 signaling pathways which are implicated in immune-mediated diseases. SAN DIEGO, June 10, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the presentation of a poster at the Antibody Engin
LONDON, ENGLAND / ACCESSWIRE / June 9, 2021 / Love Hemp Group PLC (AQSE:LIFE)(OTCQB:WRHLF), one of the UK's leading CBD and Hemp product suppliers, announces the issue of warrants and equity by the Company.Issue of warrantsThe Company has issued 15,746,325 warrants with an exercise price of 3.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...